Stem cell transplantation in Hodgkin lymphoma

References

• Cartwright R, Brincker H, Carli P et al. The rise in incidence of lymphomas in Europe, 1985–1992. Eur. J. Cancer35, 627–633 (1999).
   PubMed Web of Science ®Google Scholar
• Meyer R, Ambinder R, Stroobants S. Hodgkins lymphoma: evolving concepts with implications for practice. Hematology Am. Soc. Hematol. Educ. Program184–202 (2004).
   PubMedGoogle Scholar
• Canellos GP, Anderson JR, Propert KJ et al. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N. Engl. J. Med.327, 1478–1483 (1992).
   PubMed Web of Science ®Google Scholar
• Diehl V, Franklin J, Pfreundschuh M et al. German Hodgkin’s Lymphoma Study Group standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N. Engl. J. Med.348, 2386–2395 (2003).
   PubMed Web of Science ®Google Scholar
• Oza AM, Ganesan TS, Leahy M et al. Patterns of survival in patients with Hodgkin’s disease: long follow up in a single centre. Ann. Oncol.4, 385–492 (1993).
   PubMed Web of Science ®Google Scholar
• Josting A, Rueffer U, Franklin J, Sieber M, Diehl V, Engert A. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood96, 1280–1286 (2000).
   PubMed Web of Science ®Google Scholar
• Appelbaum FR, Herzig GP, Ziegler JL et al. Successful engraftment of cryopreserved autologous bone marrow in patients with malignant lymphoma. Blood52, 85–95 (1978).
   PubMed Web of Science ®Google Scholar
• Philip T, Armitage JO, Spitzer G et al. High-dose therapy and autologous marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin’s lymphoma. N. Engl. J. Med.316, 1493–1498 (1987).
   PubMed Web of Science ®Google Scholar
• Carella AM, Santini G, Santoro A et al. Massive chemotherapy with non-frozen autologous bone marrow transplantation in 13 cases of refractory Hodgkin’s disease. Eur. J. Clin. Oncol.21, 607–613 (1985).
   PubMedGoogle Scholar
• Philip T, Dumont J, Teillet F et al. High dose chemotherapy and autologous bone marrow transplantation in refractory Hodgkin’s disease. Br. J. Cancer53, 737–742 (1986).
   PubMed Web of Science ®Google Scholar
• Jagannath S, Dicke KA, Armitage JO et al. High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin’s disease. Ann. Intern. Med.104, 163–168 (1986).
   PubMed Web of Science ®Google Scholar
• Copelan EA. Hematopoietic stem-cell transplantation. N. Engl. J. Med.354, 1813–1826 (2006).
   PubMed Web of Science ®Google Scholar
• Anderson JE, Litzow MR, Appelbaum FR et al. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience. J. Clin. Oncol.11, 2342–2350 (1993).
   PubMed Web of Science ®Google Scholar
• Akpek G, Ambinder RF, Piantadosi S et al. Long-term results of blood and marrow transplantation for Hodgkin's lymphoma. J. Clin. Oncol.19, 4314–4321 (2001).
   PubMed Web of Science ®Google Scholar
• Porter DL, Connors JM, Van Deerlin VM et al. Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies. J. Clin. Oncol.17, 1234–1243 (1999).
   PubMed Web of Science ®Google Scholar
• Schmitz N, Linch DC, Dreger P et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet347, 353–357 (1996).
   PubMed Web of Science ®Google Scholar
• Yung L, Linch D. Hodgkin’s lymphoma. Lancet361, 943–951 (2003).
   PubMed Web of Science ®Google Scholar
• Bonadonna G, Santoro A, Gianni AM et al. Primary and salvage chemotherapy in advanced Hodgkin’s disease: the Milan Cancer Institute experience. Ann. Oncol.2(Suppl. 1), 9–16 (1991).
   PubMed Web of Science ®Google Scholar
• Viviano S, Bonfante V, Di Nicola S et al. Long-term results of high-dose chemotherapy (HDCT) supported by hematopoietic circulating (ASCT) or bone marrow (BMT) stem cell autografting as first salvage treatment for refractory or relapsed Hodgkin’s lymphoma. ASCO Annual Meeting 2006, Atlanta, GA, USA (2006) (General Poster Session 7567).
   Google Scholar
• Sweetenham JW, Taghipou G, Linch DC, Goldstone AH. Thirty percent of adult patients with primary refractory Hodgkin's disease are progressive free at 5 years after high-dose therapy and autologous stem cell transplantation: data from 290 patients reported to the EBMT. Blood8(Suppl. 1), A486 (1996).
   Google Scholar
• Longo D, Duffey P, Young R. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin’s disease after combination chemotherapy: the low probability for cure. J. Clin. Oncol.10, 210–218 (1992).
   PubMed Web of Science ®Google Scholar
• Bonfante V, Santoro A, Viviani S. Outcome of patients with Hodgkin’s disease failing after primary MOPP/ABVD. J. Clin. Oncol.15, 528–534 (1997).
   PubMed Web of Science ®Google Scholar
• Josting A, Franklin J, May M et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin lymphoma registered in the database of the German Hodgkin Lymphoma Study Group (GHSG). J. Clin. Oncol.20, 221–230 (2002).
   PubMed Web of Science ®Google Scholar
• Bartlett N. Therapies for relapsed Hodgkin lymphoma: transplant and non-transplant approaches including immunotherapy. Hematology Am. Soc. Hematol. Educ. Program245–251 (2005).
   PubMedGoogle Scholar
• Yahalom J, Gulati S. Autologous bone marrow transplantation for refractory or relapsed Hodgkin’s disease: the Memorial Sloan–Kettering Cancer Center experience using high-dose chemotherapy with or without hyperfractionated accelerated total lymphoid irradiation. Ann. Oncol.2(Suppl. 2), 67–71 (1991).
   PubMed Web of Science ®Google Scholar
• Svoboda J, Andreadis C, Elstrom R et al. Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplant.38, 211–216 (2006).
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Glassman JR, Wuest D et al. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma. Clin. Cancer Res.4, 311–316 (1998).
   PubMed Web of Science ®Google Scholar
• Rodriguez J, Rodriguez MA, Fayad L et al. ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin’s disease. Blood11, 3632–3636 (1999).
   Google Scholar
• Pfreundschuh MG, Rueffer U, Lathan B et al. Dexa-BEAM in patients with Hodgkin’s disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin’s Disease Study Group. J. Clin. Oncol.12, 580–586 (1994).
   PubMed Web of Science ®Google Scholar
• Colwill R, Crump M, Couture F et al. Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin’s disease before intensive therapy and autologous bone marrow transplantation. J. Clin. Oncol.13, 396–402 (1995).
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Nimer SD, Zelenetz AD et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin’s disease: analysis by intent to treat and development of a prognostic model. Blood97, 616–623 (2001).
   PubMed Web of Science ®Google Scholar
• Josting A, Rudolph C, Reiser M et al. Time-intensified dexamethasone/cisplatin/ cytarabine: an effective salvage therapy with low toxicity in patients with relapsed or refractory Hodgkin’s diseases. Ann. Oncol.10, 1628–1635 (2002).
   Google Scholar
• Aparicio J, Segura A, Garcera S et al. ESHAP is an active regimen for relapsing Hodgkin’s disease. Ann. Oncol.10, 593–595 (1999).
   PubMed Web of Science ®Google Scholar
• Baetz T, Belch A, Couban S et al. Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin’s disease: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann. Oncol.14, 1762–1767 (2003).
   PubMed Web of Science ®Google Scholar
• Ng M, Waters J, Cunningham D et al. Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. Br. J. Cancer92, 1352–1357 (2005).
   PubMed Web of Science ®Google Scholar
• Gutierrez-Delgado F, Holmberg L, Hooper H et al. Autologous stem cell transplantation for Hodgkin’s disease: busulfan, melphalan and thiopeta compared to a radiation-based regimen. Bone Marrow Transplant.32, 279–285 (2003).
   PubMed Web of Science ®Google Scholar
• Sureda A, Arranz R, Iriondo A et al. Autologous stem-cell transplantation for Hodgkin’s disease: results and prognostic factors in 494 patients from the Grupo Espanol de Linfomas/Transplante Autologo de Medula Osea Spanish Cooperative Group. J. Clin. Oncol.19, 1395–1404 (2001).
   PubMed Web of Science ®Google Scholar
• Chen CI, Abraham R, Tsang R et al. Radiation-associated pneumonitis following autologous stem cell transplant: predictive factors, disease characteristics and treatment outcomes. Bone Marrow Transplant.27, 117–182 (2001).
   PubMedGoogle Scholar
• Linch DC, Winfield D, Goldstone AH et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet341, 1051–1054 (1993).
   PubMed Web of Science ®Google Scholar
• Schmitz N, Pfistner B, Sextro M et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet359, 2065–2071 (2002).
   PubMed Web of Science ®Google Scholar
• Schmitz N, Haverkamp H, Josting A et al. Long term follow up in relapsed Hodgkin’s disease (HD): updated results of the HD-R1 study comparing conventional chemotherapy (cCT) to high-dose chemotherapy (HDCT) with autologous haemopoetic stem cell transplantation (ASCT) of the German Hodgkin Study Group (GHSG) and the Working Party Lymphoma of the European Group for Blood and Marrow Transplantation (EBMT). ASCO Annual Meeting 2005 Orlando, Florida, USA (2005) (23 Abstract 6508a).
   Google Scholar
• Hasenclever D, Diehl V, Armitage JO et al. A prognostic score for advanced Hodgkins disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N. Engl. J. Med.339, 1506–1514 (1998).
   PubMed Web of Science ®Google Scholar
• Bierman PJ, Lynch JC, Bociek RG et al. The International Prognostic Factors Project Score for advanced Hodgkin’s disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation. Ann. Oncol.13, 1370–1377 (2002).
   PubMed Web of Science ®Google Scholar
• Federico M, Bellei M, Brice P et al. High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkins lymphoma responding to front-line therapy. J. Clin. Oncol.21, 2320–2325 (2003).
   PubMed Web of Science ®Google Scholar
• Saghatchian M, Djeridane M, Escoffre-Barbe M et al. Very high risk Hodgkin’s disease (HD): ABVD 4 cycles plus BEAM followed by autologous stem cell transplantation (ASCT) and radiotherapy (RT) versus intensive chemotherapy (3 cycles) (INT-CT) and RT. Four-year results of the GOELAMS H97-GM multicentric randomised trial (abstract). Proc. Am. Soc. Clin. Oncol.21, A263 (2002).
   Google Scholar
• Moskowitz CH, Kewalramani T, Nimer S, Gonzalez M, Zelenetz A, Yahalom J. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin’s disease. Br. J. Haematol.124, 645–652 (2004).
   PubMed Web of Science ®Google Scholar
• Klimm B, Schnell R, Diehl V, Engert A. Current treatment and immunotherapy of Hodgkin’s lymphoma. Haematologica90, 1680–1692 (2005).
   PubMed Web of Science ®Google Scholar
• Josting A, Rudolph C, Mapara M et al. Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann. Oncol.16, 116–123 (2005).
   PubMed Web of Science ®Google Scholar
• Glossman JP, Josting A, Pfistner B, Paulus U, Engert A. A randomized trial of chemotherapy with carmustine, etoposide, cytarabine, and melphalan (BEAM) plus peripheral stem cell transplantation (PBSCT) vs single-agent high-dose chemotherapy followed by BEAM plus PBSCT in patients with relapsed Hodgkin’s disease (HD-R2). Ann. Haematol.81, 424–429 (2002).
   PubMedGoogle Scholar
• Paltiel O, Rubinstein C, Or R et al. Factors associated with survival in patients with progressive disease following autologous transplant for lymphoma. Bone Marrow Transplant.31, 565–569 (2003).
   PubMed Web of Science ®Google Scholar
• Devizzi L, Santoro A, Bonfante V et al. Vinorelbine: an active drug for the management of patients with heavily pretreated Hodgkin’s disease. Ann. Oncol.5, 817–820 (1994).
   PubMed Web of Science ®Google Scholar
• Little R, Wittes RE, Longo DL, Wilson WH. Vinblastine for recurrent Hodgkin’s disease following autolgous bone marrow transplant. J. Clin. Oncol.16, 584–588 (1998).
   PubMed Web of Science ®Google Scholar
• Venkatesh H, Di Bella N, Flynn TP, Vellek MJ, Boehm KA, Asmar L. Results of a Phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin’s lymphoma. Clin. Lyphoma.5, 110–115 (2004).
   Google Scholar
• Lin TS, Avalos BR, Penza SL, Marcucci G, Elder PJ, Copelan EA. Second autologous stem cell transplant for multiple relapsed Hodgkin’s disease. Bone Marrow Transplant.29, 763–767 (2002).
   Google Scholar
• Vandenberghe E, Pearce R, Taghipor G, Fouillard L, Goldstone A. Role of a second transplant in the management of poor-prognosis lymphoma: a report from the European Blood and Bone Marrow Registry. J. Clin. Oncol.15, 1595–1600 (1997).
   PubMed Web of Science ®Google Scholar
• Jones RJ, Ambinder RF, Piantadosi S, Santos GW. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood77, 649–653 (1991).
   PubMed Web of Science ®Google Scholar
• Gajewski JL, Phillips GL, Sobocinski KA et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin’s disease. J. Clin. Oncol.14, 572–578 (1996).
   PubMed Web of Science ®Google Scholar
• Milpied N, Fielding AK, Pearce RM et al. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin’s disease. European Group for Blood and Bone Marrow Transplantation. J. Clin. Oncol.14, 1291–1296 (1996).
   PubMed Web of Science ®Google Scholar
• Carella AM, Champlin R, Slavin S, McSweeney P, Storb R. Mini-allografts: ongoing trials in humans. Bone Marrow Transplant.25, 345–350 (2000).
   PubMed Web of Science ®Google Scholar
• Sureda A, Robinson S, Ruiz de Elvira C. Non-myeloablative allogeneic stem cell transplantation reduces transplant related mortality in comparison with conventional alloegneic transplantation in relapsed or refractory Hodgkin’s disease: results of the European Group for Blood and Marrow Transplantation. Blood102(Suppl. 1), 1461 (2003) (Abstract 692)>.
   Google Scholar
• Baron F, Storb R. Current roles for allogeneic hematopoietic cell transplantation following nonmyeloablative or reduced-intensity conditioning. Clin. Adv. Hematol. Oncol.3, 799–819 (2005).
   PubMedGoogle Scholar
• Peggs KS, Hunter A, Chopra R et al. Clinical evidence of graft-versus-Hodgkin’s-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet365, 1934–1941 (2005).
   PubMed Web of Science ®Google Scholar
• Carella AM, Cavaliere M, Lerma E et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic periperhal-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin’s disease and non-Hodgkin’s lymphoma. J. Clin. Oncol.18, 3918–3924 (2000)
   PubMed Web of Science ®Google Scholar
• Josting A, Nogova L, Franklin J et al. Salvage radiotherapy in patients with relapsed and refractory Hodgkin’s lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. J. Clin. Oncol.23, 1522–1529 (2005).
   PubMed Web of Science ®Google Scholar
• Poen JC, Hoppe RT, Horning SJ. High-dose therapy and autologous bone marrow transplantation for relapsed/refractory Hodgkin’s disease: the impact of involved field radiotherapy on patterns of failure and survival. Int. J. Radiat. Oncol. Biol. Phys.36, 3–12 (1996).
   PubMed Web of Science ®Google Scholar
• Wendland MM, Asch JD, Pulsipher MA, Thomson JW, Shrieve DC, Gaffney DK. The impact of involved field radiation therapy for patients receiving high-dose chemotherapy followed by hematopoietic progenitor cell transplant for the treatment of relapsed or refractory Hodgkin disease. Am J. Clin. Oncol.29(2), 189–195 (2006).
   PubMed Web of Science ®Google Scholar
• Yahalom J. Transformation in the use of radiation therapy of Hodgkin lymphoma: new concepts and indications lead to modern field design and are assisted by PET imaging and intensity modulated radiation therapy (IMRT). Eur. J. Haematol. Suppl.66, 90–97 (2005).
   PubMedGoogle Scholar
• Forrest DL, Hogge DE, Nevill TJ et al. High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin’s lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation. J. Clin. Oncol.23, 7994–8002 (2005).
   PubMed Web of Science ®Google Scholar
• Deeg HJ, Socie G. Malignancies after hematopoietic stem cell transplantation: many questions, some answers. Blood91, 1833–1844 (1998).
   PubMed Web of Science ®Google Scholar
• Krishnan A, Bhatia S, Slovak ML et al. Predictors of therapy-related leukaemia and myelodysplasia following autologous transplantation for lymphoma: as assessment of risk factors. Blood95, 1588–1593 (2000).
   PubMed Web of Science ®Google Scholar
• Metayer C, Curtis RE, Vose J et al. Myelodysplastic syndrome and acute myeloid leukaemia after autotransplantation for lymphoma: a multicenter case-control study. Blood101, 2015–2023 (2003).
   PubMed Web of Science ®Google Scholar
• Dores GM, Metayer C, Curtis RE et al. Second malignant neoplasms among long-term survivors of Hogkin’s disease: a population-based evaluation over 25 years. J. Clin. Oncol.20, 3484–3494 (2002).
   PubMed Web of Science ®Google Scholar
• Van Leeuwen FE, Klokman WJ, Veer MB et al. Long-term risk of second malignancy in survivors of Hodgkin’s disease treated during adolescence or young adulthood. J. Clin. Oncol.18, 487–497 (2000).
   PubMed Web of Science ®Google Scholar
• Andre M, Henry-Amar M, Blaise D et al. Treatment-related deaths and second cancer risk after autologous stem cell transplantation for Hodgkin’s disease. Blood92, 1933–1940 (1998).
   PubMed Web of Science ®Google Scholar
• Lavoie JC, Connors JM, Phillips GL et al. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood106, 1473–1478 (2005).
   PubMed Web of Science ®Google Scholar
• Chopra R, McMillan AK, Linch DC et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor risk Hodgkin’s disease: a single-center eight-year study of 155 patients. Blood81, 1137–1145 (1993).
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Ringden O. Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant.11, 321–334 (2005).
   PubMed Web of Science ®Google Scholar
• Schnell R, Dietlein M, Staak OJ et al. Treatment of refractory Hodgkin’s lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody. J. Clin. Oncol.23, 4669–4678 (2005).
   PubMed Web of Science ®Google Scholar
• Rehwald U, Schulz H, Reiser M et al. Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood101, 420–424 (2003).
   PubMed Web of Science ®Google Scholar
• Younes A, Romaguera J, Hagemeister et al. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer98, 310–314 (2003).
   PubMed Web of Science ®Google Scholar